HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Synthetic Conjugated Estrogens-B and Postmenopausal Nocturnal Vasomotor Symptoms: A Randomized Controlled Trial
OBJECTIVE : To evaluate two doses of oral synthetic conjugated estrogens-B tablets compared with placebo on the frequency of awakenings result ing from nocturnal vasomotor symptoms in postmenopausal women over a 12-week treatment period . METHODS : A double-blind , r and omized , placebo-controlled multicenter study enrolled a total of 157 women who were experiencing daytime vasomotor symptoms and a minimum of at least three nocturnal awakenings per night as a result of hot flushes . Participants were evenly r and omized to one of three treatment groups ( 0.3 mg , 0.625 mg , or matching placebo ) and treated for up to 12 weeks . Subjective sleep quality also was assessed . RESULTS : Significantly greater reductions from baseline in the weekly mean frequency of awakenings result ing from hot flushes occurred for participants r and omized to either synthetic conjugated estrogens-B dose relative to placebo ( mean reductions , 3.55 , P=.004 , and 4.65 , P<.001 for 0.3 mg and 0.625 mg , respectively ) . In addition , a significantly greater proportion of participants at either estrogen dose had complete elimination of nocturnal awakenings ( 36.5 % for 0.3 mg , 34 % for 0.625 mg compared with 9.8 % for placebo ; P⩽.002 ) with a general finding of improved sleep based on actigraphy data . No differences were observed in measures of sleep quality or daytime sleepiness . CONCLUSION : In this symptomatic postmenopausal population of women experiencing sleep disruption result ing from nocturnal vasomotor symptoms , a daily dose of synthetic conjugated estrogens-B as low as 0.3 mg appears to be effective in treating nocturnal hot flushes that lead to unwanted awakenings . CLINICAL TRIAL REGISTRATION : Clinical Trials.gov , www . clinical trials.gov , NCT00592839 . LEVEL OF EVIDENCE :
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .